121 related articles for article (PubMed ID: 22234635)
1. Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: similarity to the original drug.
Glauser BF; Vairo BC; Oliveira SN; Cinelli LP; Pereira MS; Mourão PA
Thromb Haemost; 2012 Feb; 107(2):302-14. PubMed ID: 22234635
[TBL] [Abstract][Full Text] [Related]
2. Structural and functional analyses of biosimilar enoxaparins available in Brazil.
Oliveira SN; Santos GR; Glauser BF; Capillé NV; Queiroz IN; Pereira MS; Pomin VH; Mourão PA
Thromb Haemost; 2015 Jan; 113(1):53-65. PubMed ID: 25252953
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
[TBL] [Abstract][Full Text] [Related]
4. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
5. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
[TBL] [Abstract][Full Text] [Related]
7. Recurrent life-threatening deep tissue hematomas after switching to generic enoxaparin: a report and perspective on the approval process for biological compounds.
Kaffenberger BH; Bekaii-Saab T
Clin Appl Thromb Hemost; 2012; 18(1):104-6. PubMed ID: 21873360
[TBL] [Abstract][Full Text] [Related]
8. Propositional debate on biosimilar enoxaparin in Brazil.
Mourão PA; Glauser BF; Vairo BC; Pereira MS
Arq Bras Cardiol; 2012 Jan; 98(1):e11-4. PubMed ID: 22323327
[TBL] [Abstract][Full Text] [Related]
9. Generic versions of enoxaparin available for clinical use in Brazil are similar to the original drug.
Glauser BF; Vairo BC; Oliveira CP; Cinelli LP; Pereira MS; Mourão PA
J Thromb Haemost; 2011 Jul; 9(7):1419-22. PubMed ID: 21535394
[No Abstract] [Full Text] [Related]
10. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
[TBL] [Abstract][Full Text] [Related]
11. Skin necrosis induced by generic enoxaparin.
Gucalp A; Parameswaran R; Lacouture M; Abou-Alfa G; Soff G
Am J Hematol; 2013 Apr; 88(4):339. PubMed ID: 23450519
[No Abstract] [Full Text] [Related]
12. Low-molecular-weight heparin in patients with advanced cirrhosis.
Bechmann LP; Sichau M; Wichert M; Gerken G; Kröger K; Hilgard P
Liver Int; 2011 Jan; 31(1):75-82. PubMed ID: 20958919
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the biological activity of 2 formulations of enoxaparin in 12 healthy volunteers.
Sharma V; Madhu S; Natarajan P; Muniyandi G; Jaiswal V; Saxena R
Clin Appl Thromb Hemost; 2010 Aug; 16(4):387-93. PubMed ID: 19671565
[TBL] [Abstract][Full Text] [Related]
14. Structural and pharmacological profile of generic enoxaparins used in Brazil.
Lima MA; de Farias EH; Gray A; Sadeghi N; Gesteira TF; Cavalheiro RP; Hoppensteadt D; Fareed J; Sassaki GL; Nader HB
Clin Appl Thromb Hemost; 2012 Jul; 18(4):379-86. PubMed ID: 22395574
[TBL] [Abstract][Full Text] [Related]
15. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
16. An open label, non-randomized, prospective clinical trial evaluating the immunogenicity of branded enoxaparin versus biosimilars in healthy volunteers.
Gomes M; Ramacciotti E; Hoppensteadt D; Walenga JM; Lewis B; Thethi I; Fareed J
Clin Appl Thromb Hemost; 2011 Feb; 17(1):66-9. PubMed ID: 21220365
[TBL] [Abstract][Full Text] [Related]
17. Thromboelastographic evaluation of blood coagulation in the presence of branded and generic enoxaparins.
Walenga JM; Jeske WP; Escalante V; Hoppensteadt D; Fareed J; Bakhos M
Int Angiol; 2012 Dec; 31(6):517-25. PubMed ID: 23222929
[TBL] [Abstract][Full Text] [Related]
18. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulation in cirrhosis patients: what don't we know?
Northup PG; Intagliata NM
Liver Int; 2011 Jan; 31(1):4-6. PubMed ID: 21092072
[No Abstract] [Full Text] [Related]
20. Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonization.
Harenberg J
Clin Appl Thromb Hemost; 2011; 17(6):E158-64. PubMed ID: 21406409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
